A phase II trial of Triapine® (NSC# 663249) and gemcitabine as second line treatment of advanced non-small cell lung cancer: Eastern Cooperative Oncology Group Study 1503

BACKGROUND: The objective of ECOG 1503 was to determine the response rate of this combination in the second-line treatment of advanced NSCLC. METHODS: Triapine 105 mg/m(2) IV on days 1, 8, and 15, and gemcitabine 1,000 mg/m(2) on days 1, 8, and 15, of a 28 day cycle. RESULTS: Eighteen patients enrol...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Principais autores: Traynor, Anne M., Lee, Ju-Whei, Bayer, Gerald K., Tate, John M., Thomas, Sachdev P., Mazurczak, Miroslaw, Graham, David L., Kolesar, Jill M., Schiller, Joan H.
Formato: Artigo
Idioma:Inglês
Publicado em: 2009
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3045859/
https://ncbi.nlm.nih.gov/pubmed/19238328
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-009-9230-z
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados